Get research updatesSchizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.
Researchers compared HS-10380 Low Dose, HS-10380 Medium dose, HS-10380 High Dose, Aripiprazole and placebo to find out how the approaches affected psychotic symptoms in adults with schizophrenia.
This study has finished and is no longer accepting participants.
In ShanghaiThis study evaluated the safety of SEP-363856 for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including GlendaleThis study evaluated the safety and effectiveness of Aripiprazole for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including AnaheimRandomized, Multi-center, Open Label Trial Comparing Risperidone Depot (Microspheres) and Olanzapine Tablets in Patients With Schizophrenia or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Location not clearly listedA Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia Taking Antipsychotic Medications (GRATITUDE II)
This study has finished and is no longer accepting participants.
Multiple locations, including Bentonville
An Observational Study for Schizophrenia Relapse Prediction
This study has finished and is no longer accepting participants.
Multiple locations, including AhmedabadA Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Garden GroveA Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Electrophysiology of ANAVEX3-71 in Adult Patients With Schizophrenia in a Multiple Ascending Dose Study (Part A), Followed by a Double-Blind, Randomized, Placebo-Controlled Study (Part B)
This study is no longer accepting new participants.
In MarltonResearchers compared Elpipodect and placebo, tracking side effects to assess safety and tolerability in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Garden GroveRisperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Location not clearly listedResearchers are comparing LY2140023 and placebo to find out how the approaches affect psychotic symptoms in people with schizophrenia.
This study ended early.
Multiple locations, including WichitaA 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care (SOC) Compared to Placebo With SOC in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Garden GroveWe gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.